Valbiotis Stock

Valbiotis EBIT per Employee

The EBIT per Employee of Valbiotis (ALVAL.PA) as of Aug 5, 2026 is -289,527.78 EUR. In the previous year, EBIT per Employee was -199,444.44 EUR — a change of 45.17% (lower).

EBIT per Employee

-289,527.78EUR

YoY

45.17%

Last updated:

EBIT per Employee of Valbiotis is 2026 -289,527.78 EUR. EBIT per Employee of Valbiotis was 2025 -199,444.44 EUR. It decreases by 45.17% lower compared to the previous year.
Access this data via the Eulerpool API

Valbiotis Stock analysis

What does Valbiotis do? Valbiotis SA is a French company specializing in the research and development of new and innovative treatment options based on plant-derived ingredients. The company was founded in 2014 by Sebastien Peltier, an experienced employee in the pharmaceutical industry, who wanted to search for new and effective therapeutic possibilities. Valbiotis' business model is based on identifying and utilizing new plant-derived ingredients to develop therapies that cater to market needs. The company works closely with various partners, universities, and research organizations to ensure that their products are based on the latest scientific findings. One of Valbiotis' main areas of focus is the development of products to support metabolism and metabolic health. They utilize solutions based on a plant-derived ingredient called TOTUM-63, which aims to treat and prevent risk factors such as obesity, insulin resistance, and metabolic diseases like Type 2 diabetes. Valbiotis has also established a comprehensive research department to explore further applications for their plant-derived ingredients, including cardiovascular diseases and neurodegenerative diseases like Alzheimer's. One of Valbiotis' most well-known products is TOTUM-63, a plant-derived ingredient that has positive effects on metabolism. TOTUM-63 consists of four different plant-derived ingredients and is intended to restore balance to metabolism and support the body in combating risk factors such as obesity and Type 2 diabetes. The company is currently seeking further promising applications for TOTUM-63. Valbiotis has also formed partnerships with major pharmaceutical companies such as Nestlé Health Science and Nestlé Research to fund their research and optimize the use of their plant-derived ingredients. Additionally, Valbiotis collaborates with various universities and research institutions to incorporate the latest scientific findings into their products. Overall, Valbiotis is one of the most promising companies in the pharmaceutical industry focused on plant-derived ingredients. The company has developed a wide range of products and applications and works closely with various partners to develop innovative therapy options based on plant-derived ingredients. Valbiotis is well-positioned to achieve further growth in the future and treat and prevent diseases in a new way. Valbiotis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valbiotis stock

EBIT per Employee of Valbiotis is -289,527.78 EUR in 2026.

EBIT per Employee of Valbiotis changed from -199,444.44 EUR to -289,527.78 EUR, representing a 45.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Valbiotis since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Valbiotis historically and in real time.

Access this data via the Eulerpool API

Workforce — Valbiotis

All Key Metrics — Valbiotis